Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT111 and cemiplimab in PD-1/PD-L1-refractory unresectable stage III/IV melanoma
2020-002195-12Phase 2Active
- Sponsor
- BioNTech SE
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cutaneous melanoma (CM) comparing BNT111 + cemiplimab, BNT111 monotherapy and cemiplimab monotherapy (3 arms). Primary endpoint: Objective response rate by BICR for BNT111 + cemiplimab. Started Dec 2020; status: active.
02
Drugs
enomimerancemiplimab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2020-002195-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002195-12.